Hologic, Inc. (NASDAQ:HOLX – Get Rating) has earned a consensus recommendation of “Hold” from the sixteen research firms that are covering the company, MarketBeat reports. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $86.00.
A number of equities analysts recently issued reports on the company. Raymond James boosted their price objective on Hologic from $95.00 to $100.00 in a report on Tuesday, May 2nd. Morgan Stanley boosted their price objective on Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a report on Friday, February 3rd. StockNews.com assumed coverage on Hologic in a report on Thursday, May 18th. They set a “buy” rating for the company. SVB Leerink boosted their price objective on Hologic from $90.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 2nd. Finally, Mizuho boosted their price objective on Hologic from $92.00 to $95.00 in a report on Tuesday, May 2nd.
Insider Transactions at Hologic
In other news, insider Essex D. Mitchell sold 2,390 shares of the business’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $83.73, for a total value of $200,114.70. Following the completion of the transaction, the insider now directly owns 7,212 shares of the company’s stock, valued at approximately $603,860.76. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.66% of the company’s stock.
Institutional Inflows and Outflows
Hologic Price Performance
Shares of Hologic stock opened at $79.03 on Friday. The stock has a market cap of $19.45 billion, a price-to-earnings ratio of 26.43 and a beta of 1.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.69 and a current ratio of 4.41. The stock has a 50 day moving average price of $82.13 and a 200-day moving average price of $79.57. Hologic has a one year low of $59.78 and a one year high of $87.88.
Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Monday, May 1st. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.18. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $957.53 million. Hologic had a return on equity of 19.39% and a net margin of 18.56%. The company’s quarterly revenue was down 28.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 EPS. Equities analysts expect that Hologic will post 3.89 EPS for the current year.
Hologic Company Profile
Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.